Nocandia SB65 mg

Nocandia SB is a broad-spectrum triazole antifungal used to treat a range of fungal infections. Its approved and guideline-supported uses include:

Established / FDA-Approved Uses

• Onychomycosis of the toenail or fingernail caused by dermatophytes, in patients with normal cardiac function.
• Systemic fungal infections, including blastomycosis (pulmonary and extrapulmonary) and histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis).
• Invasive aspergillosis in patients who are intolerant of, or refractory to, amphotericin B therapy.
• Oropharyngeal and esophageal candidiasis, including in immunocompromised patients.

Guideline-Supported / Widely Used Indications

• Dermatophyte infections of the skin such as tinea corporis, tinea cruris, tinea pedis, and tinea manuum.
• Pityriasis (tinea) versicolor caused by Malassezia species.
• Vulvovaginal candidiasis, as a short-course oral alternative to topical therapy.

Off-Label / Specialist Use

• Prophylaxis of invasive fungal infections in selected high-risk, severely immunocompromised patients (e.g. prolonged neutropenia, graft-versus-host disease), under specialist supervision.
• Maintenance or step-down therapy after initial treatment of certain systemic mycoses with other antifungal agents.

The specific organism, infection site, and formulation determine the appropriate regimen; a physician's assessment, often supported by laboratory confirmation, is required before starting Nocandia SB.

Each capsule of Itraconazole typically contains 100 mg of itraconazole as drug-coated sugar spheres in a hard gelatin capsule. Itraconazole oral solution typically contains 10 mg/mL solubilized with hydroxypropyl-β-cyclodextrin. Tablet (200 mg) and SUBA (Super Bioavailability) capsule formulations (50 mg or 65 mg) are available in some markets. Different formulations of Itraconazole are not bioequivalent and must not be interchanged without medical advice; always confirm strength and formulation with the dispensing pharmacist.

Nocandia SB is a synthetic triazole antifungal agent used to treat a wide range of superficial and systemic fungal infections. It works by inhibiting a fungal enzyme required to build the fungal cell membrane, stopping fungal growth. Nocandia SB is available as oral capsules and an oral solution, which differ in how they should be taken with regard to food. Treatment courses range from a single day (for some vaginal infections) to several months (for nail or deep tissue infections), and the drug carries a boxed warning about its effect on heart muscle function, so it is not suitable for everyone.

Systemic Antifungal - Triazole Derivative

Itraconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent 14α-demethylase, an enzyme that converts lanosterol to ergosterol. Ergosterol is essential to the fungal cell membrane; its depletion, together with accumulation of toxic sterol precursors, disrupts membrane structure and function and inhibits fungal growth (fungistatic, and fungicidal against some organisms at higher concentrations).

Pharmacokinetics: Absorption of the capsule formulation is enhanced by food and an acidic gastric environment, whereas the oral solution is better absorbed on an empty stomach due to its cyclodextrin carrier. Itraconazole is highly protein-bound (>99%), extensively metabolized in the liver by CYP3A4 to an active metabolite (hydroxy-itraconazole), and has a long elimination half-life that increases with continued dosing due to saturable metabolism. It penetrates poorly into cerebrospinal fluid but achieves high concentrations in skin, nails, and adipose tissue.

Nocandia SB capsules should be swallowed whole (not chewed) immediately after a full meal, since food and gastric acidity are needed for reliable absorption; taking capsules on an empty stomach can markedly reduce drug levels. In contrast, Nocandia SB oral solution should be taken without food, and for oropharyngeal candidiasis should be swished in the mouth before swallowing. Capsules and oral solution are not interchangeable milligram-for-milligram. Because capsule absorption requires stomach acid, drugs that reduce gastric acid (proton pump inhibitors, H2-blockers, antacids) can significantly lower Nocandia SB levels - see Interactions for guidance on spacing these medicines apart. Take doses at the same time each day and complete the full prescribed course.

Nocandia SB and its major metabolite are potent inhibitors of CYP3A4 and P-glycoprotein, giving it a large potential for drug interactions.

Contraindicated combinations

• Certain statins (lovastatin, simvastatin) - risk of severe myopathy/rhabdomyolysis.
• Oral midazolam and triazolam - risk of profound, prolonged sedation/respiratory depression.
• Ergot alkaloids (dihydroergotamine, ergotamine, ergometrine/methylergometrine) - risk of ergotism and peripheral ischemia.
• QT-prolonging agents such as quinidine, dofetilide, and disopyramide - risk of life-threatening arrhythmias.
• Cisapride and pimozide - risk of cardiotoxicity.
• Certain calcium channel blockers (felodipine, nisoldipine) and other agents including lomitapide, ranolazine, irinotecan, ivabradine, eplerenone, and naloxegol.

Combinations requiring caution or dose adjustment

• Methadone - increased levels; monitor for QT prolongation and sedation.
• Digoxin - increased digoxin levels; monitor for toxicity.
• Warfarin and other anticoagulants - enhanced anticoagulant effect; monitor INR.
• Certain immunosuppressants (cyclosporine, tacrolimus, sirolimus), some protease inhibitors, and some benzodiazepines and calcium channel blockers - increased levels; dose reduction/monitoring often needed.
• Rifampin, rifabutin, phenytoin, carbamazepine and other strong CYP3A4 inducers - substantially reduce Nocandia SB levels, risking treatment failure; concurrent use is generally avoided.

Interactions affecting absorption

• Antacids, H2-receptor blockers, and proton pump inhibitors reduce absorption of Nocandia SB capsules by raising gastric pH; separate dosing where possible.

This is not an exhaustive list. Give a physician or pharmacist a full list of current medicines before starting Nocandia SB.

Most people tolerate Nocandia SB well, but side effects can occur.

Common (usually mild)

• Nausea, abdominal pain, diarrhea, or dyspepsia
• Headache and dizziness
• Rash
• Mild, transient elevation of liver enzymes

Less common but important

• Edema, particularly of the lower limbs
• Hypertension
• Hypokalemia (more likely with longer courses or higher doses)

Rare but serious - seek medical attention

• Signs of liver injury: yellowing of skin/eyes, dark urine, unusual fatigue, loss of appetite, pale stools (see Precautions and Warnings).
• Signs of heart failure: shortness of breath, swelling of legs/ankles, unexplained fatigue, sudden weight gain.
• Signs of a severe allergic reaction: facial/throat swelling, severe rash, difficulty breathing.
• Peripheral neuropathy (numbness/tingling) with prolonged use.
• Hearing loss (rare, sometimes reversible).

Report any severe, persistent, or worsening side effect to a physician promptly.

Pregnancy: Nocandia SB should generally be avoided during pregnancy due to a theoretical risk of fetal harm seen in animal studies, and it is not recommended for non-life-threatening indications (such as onychomycosis or pityriasis versicolor) in pregnant women or women planning pregnancy. It should be used during pregnancy only for potentially life-threatening fungal infections, and only if the anticipated benefit to the mother clearly justifies the potential risk to the fetus, under close physician supervision. Women of childbearing potential should use effective contraception during treatment and for a period after stopping Nocandia SB, as advised by their physician, given its long elimination half-life.

Lactation: Nocandia SB passes into breast milk in small amounts. Breastfeeding is generally not recommended during treatment unless a physician determines the benefit to the mother outweighs the potential risk to the nursing infant. Consult a physician before breastfeeding while taking Nocandia SB.

Boxed Warning - Cardiac Effects

Nocandia SB has a negative inotropic effect on the heart. It should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction, such as congestive heart failure (CHF) or a history of CHF (see Contraindications). For more serious, potentially life-threatening indications, the benefits and risks should be individually assessed, particularly in patients with heart failure risk factors; if signs or symptoms of heart failure develop during treatment, Nocandia SB should be discontinued and the patient reassessed.

Hepatotoxicity

Rare cases of serious hepatotoxicity, including liver failure and death, have been reported with Nocandia SB, some occurring within the first month of treatment. Liver function tests are recommended before starting treatment and periodically during longer courses, especially in patients with pre-existing liver disease or abnormal liver enzymes. Seek immediate medical attention for signs of liver injury (see Side Effects).

Absorption and formulation differences

Nocandia SB capsules require gastric acid and food for adequate absorption, while the oral solution is absorbed better on an empty stomach; the two formulations are not interchangeable milligram-for-milligram (see Administration).

Drug interactions

Nocandia SB is a potent CYP3A4 inhibitor with numerous contraindicated and cautioned interactions (see Interactions). A full medication review is essential before starting therapy.

Hearing loss and neuropathy

Transient or permanent hearing loss and peripheral neuropathy have been reported, particularly with prolonged treatment; report any hearing changes or numbness/tingling to a physician.

Antifungal stewardship

Take Nocandia SB exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, as incomplete or inappropriate courses may promote resistant fungal infections and treatment failure.

Reported overdose experience with Nocandia SB is limited, and symptoms would be expected to resemble an exaggeration of known side effects (e.g. nausea, vomiting, abdominal discomfort). There is no specific antidote. In case of a suspected overdose, seek immediate medical attention or contact a poison control center right away; do not attempt home treatment. Supportive care, including monitoring of vital signs and liver/cardiac function, may be provided under medical supervision; Nocandia SB is not significantly removed by hemodialysis.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of reach of children. Do not use after the expiry date printed on the pack.

Renal impairment

Use Nocandia SB with caution in patients with renal impairment; oral formulations may generally be used with monitoring, while injectable forms (where available) are typically avoided in significant renal impairment.

Hepatic impairment

Use with caution in patients with liver disease; Nocandia SB is extensively metabolized by the liver, and dose adjustment or closer monitoring of liver function may be needed. It is contraindicated in severe pre-existing liver disease unless potential benefit outweighs risk.

Elderly

Data in elderly patients are limited; use with caution given the higher likelihood of cardiac disease, polypharmacy, and reduced organ function in this age group, and monitor closely for interactions and cardiac symptoms.

Immunocompromised patients

Nocandia SB absorption may be reduced in immunocompromised patients (e.g. HIV/AIDS, neutropenia, chemotherapy), and monitoring of clinical response is warranted.

Duration of Nocandia SB therapy is highly indication-specific: as short as a single day for vulvovaginal candidiasis, one to two weeks for oropharyngeal candidiasis or tinea versicolor, two to four weeks for skin dermatophyte infections, around three months (or pulsed courses) for nail infections, and three months or longer, guided by clinical and laboratory response, for systemic infections such as blastomycosis or histoplasmosis. The physician determines the exact duration; treatment should not be stopped early even if symptoms improve, and should not be extended beyond the prescribed course without medical advice.

Antifungals > Azole Antifungals > Triazole Antifungals (second-generation triazole, related to fluconazole but with a broader spectrum including Aspergillus species)

Itraconazole works by binding to and inhibiting fungal cytochrome P450 14α-demethylase (lanosterol demethylase), the enzyme fungi need to convert lanosterol into ergosterol, the main sterol of the fungal cell membrane. By blocking this step, Itraconazole depletes ergosterol and causes accumulation of abnormal sterols in the membrane, increasing membrane permeability and disrupting membrane structure and enzyme function, ultimately inhibiting fungal growth and replication. Itraconazole has much lower affinity for human cytochrome P450 enzymes than for the fungal enzyme, underlying its selective antifungal activity, though it still meaningfully inhibits human CYP3A4, which is the basis for its many drug interactions.

C

The safety and efficacy of Nocandia SB have not been formally established for most indications in pediatric patients, and it should generally be used in children only when the treating physician judges the potential benefit to outweigh the risk, typically for serious or systemic fungal infections where alternatives are unsuitable. When used, pediatric dosing is generally weight-based (commonly around 3-5 mg/kg/day, adjusted by indication and formulation) and should be individualized and closely supervised by a pediatrician or specialist, with attention to liver function and potential drug interactions. Nocandia SB is not generally recommended for cosmetic indications (e.g. mild nail infections) in children given limited safety data. Parents/caregivers should not adjust the dose or duration without medical advice.